Precision Medicine testing approach that optimizes cancer treatment
NIPD Genetics announces the launch of NeoThetis for therapy selection, the first liquid biopsy product from the NeoSENTIA portfolio. NeoThetis is a novel, non-invasive liquid biopsy test that can guide towards the most optimal treatment for patients diagnosed with colorectal and non-small cell lung cancers (NSCLC). NeoThetis can be performed at the time of cancer diagnosis for therapy selection, or during disease progression when the patient has acquired resistance to previous treatment, for therapy re-evaluation and guiding therapy of metastatic disease.
As a non-invasive test, NeoThetis requires a simple blood draw that is painless for the patient. The most valuable advantages of NeoThetis are that it can complement tissue biopsies, and also overcome some of the challenges of tissue biopsies concerning tumor inaccessibility, and inability to assess metastatic lesions and reflect intra- and inter-tumor heterogeneity. Results are reported within 6-9 working days, ensuring treatment can begin as soon as possible. Clinical interpretation of findings, and guidance on approved targeted therapies and relevant clinical trials is provided to enable a precision medicine approach that benefits the patient’s clinical management.
NeoThetis Colorectal and NeoThetis NSCLC detect genetic mutations in 34 and 36 genes respectively that drive cancers or are associated with resistance to treatment. Both tests also assess microsatellite instability. The genes were selected after taking international clinical practice guidelines for cancer treatment into consideration. The genes selected have high clinical significance, are associated with targeted therapies, including immunotherapies, are approved for use by the FDA or EMA, are part of inclusion or exclusion criteria for clinical trials and can be indicators for therapy resistance.
Prof. Philippos Patsalis, Founder and CEO of NIPD Genetics, stated that “We are very excited for the launch of NeoThetis, as it signifies the commencing of our liquid biopsy portfolio and has tremendous therapeutic implications in the oncology field. Utilizing our decades of experience in the field of cell-free DNA, we have developed an exceptional test that highlights and reinforces the unique advantages of liquid biopsy. NeoThetis can provide invaluable information and guidance on therapy selection for cancer, and just as importantly, it can do so non-invasively with very fast results.”
NeoThetis is the first test in NIPD Genetics NeoSENTIA liquid biopsy portfolio, which will soon include liquid biopsy tests for minimal residual disease (MRD) detection and early screening. The NeoSENTIA liquid biopsy tests have been designed to empower healthcare providers to take informed decisions that enhance clinical management and treatment of patients.
To learn more about NeoThetis liquid biopsy test for therapy selection visit www.nipd.com/neothetis
